Prometic Life Sciences announced it received approval for a phase 2 clinical trial by the Swedish Medical Products Agency.
Prometic Life Sciences (TSX:PLI; OTCQX:PFSCF) announced it received approval for a phase 2 clinical trial by the Swedish Medical Products Agency (MPA) for its plasminogen therapy in patients suffering from diabetic foot ulcer.
As quoted in the press release:
The Phase 2 clinical trial is a prospective, dose escalation study of the safety, feasibility and initial efficacy of subcutaneous plasminogen for the treatment of DFU in 20 adult subjects. The study will be conducted in one study center in Sweden, under the supervision of Dr. Jan Apelqvist, an expert in the field of diabetic foot ulcers and hard to treat wounds from the Department of Endocrinology, Division of Clinical Sciences at Skane University Hospital in Malmö, Sweden.
“Diabetic foot ulcers comprise a serious, large and well-known area of unmet medical need where we believe plasminogen therapy can potentially make a difference,” said John Moran, M.D., Chief Medical Officer of Prometic. “Plasminogen is known to be essential for normal wound healing, and we have strong preclinical data showing that local injection of plasminogen improves wound healing in diabetes.”